However, even the most promising predictors of response to anti-PD-1/PD-L1 therapy in HCC, low baseline plasma levels of TGF-β or high frequency of intratumoral CD8+ or PD-1high CD8+ T cells, need to be verified using a larger number of patients in a prospective trial. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.